Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 144

Similar articles for PubMed (Select 23172714)

1.

Factors associated with spontaneous reporting of adverse drug reactions in Japan.

Yamada T, Watanabe Y, Kusama M, Sugiyama Y, Ono S.

Pharmacoepidemiol Drug Saf. 2013 May;22(5):468-76. doi: 10.1002/pds.3378. Epub 2012 Nov 21.

PMID:
23172714
2.

Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, McLernon DJ, Murphy E, Shakir S, Watson MC.

Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200. Review.

3.

Bias in spontaneous reporting of adverse drug reactions in Japan.

Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H, Nakayama T, Okugawa S, Sugimura Y, Tomita M, Takahashi Y.

PLoS One. 2015 May 1;10(5):e0126413. doi: 10.1371/journal.pone.0126413. eCollection 2015.

4.

Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.

Aldea A, García Sánchez-Colomer M, Fernández Quintana E, García Sáiz M.

Eur J Clin Pharmacol. 2012 Sep;68(9):1329-38. doi: 10.1007/s00228-012-1255-0. Epub 2012 Mar 14.

PMID:
22415248
5.

[Adverse drug reaction surveillance system in Korea].

Choi NK, Park BJ.

J Prev Med Public Health. 2007 Jul;40(4):278-84. Review. Korean.

PMID:
17693730
6.

Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.

Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL; French Association of PharmacoVigilance Centres.

Br J Clin Pharmacol. 2012 Jul;74(1):201-4. doi: 10.1111/j.1365-2125.2012.04185.x.

7.

Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study.

Johansson ML, Hägg S, Wallerstedt SM.

BMC Clin Pharmacol. 2011 Sep 7;11:14. doi: 10.1186/1472-6904-11-14.

8.

[Organization and results of drug vigilance in France].

Bégaud B, Chaslerie A, Haramburu F.

Rev Epidemiol Sante Publique. 1994;42(5):416-23. French.

PMID:
7973001
9.

Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Motola D, Vargiu A, Leone R, Conforti A, Moretti U, Vaccheri A, Velo G, Montanaro N.

Drug Saf. 2008;31(7):609-16.

PMID:
18558794
10.

Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries.

Wilbur K.

Drug Saf. 2013 Jan;36(1):25-30. doi: 10.1007/s40264-012-0001-y.

PMID:
23315293
11.

Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).

Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D.

Eur J Clin Pharmacol. 2013 Feb;69(2):237-44. doi: 10.1007/s00228-012-1321-7. Epub 2012 Jun 17.

PMID:
22706618
12.

[Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].

Montastruc JL, Lugardon S, Desboeuf K, Fernet P, Lapeyre-Mestre M.

Bull Acad Natl Med. 2008 Feb;192(2):421-30; discussion 430-1. French.

PMID:
18819693
13.

A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL; Association of French PharmacoVigilance Centres.

Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):285-8. doi: 10.1002/pds.2307. Epub 2011 Dec 8.

PMID:
22162094
14.

A prospective analysis of the preventability of adverse drug reactions reported in Sweden.

Lövborg H, Eriksson LR, Jönsson AK, Bradley T, Hägg S.

Eur J Clin Pharmacol. 2012 Aug;68(8):1183-9. doi: 10.1007/s00228-012-1237-2. Epub 2012 Feb 19.

PMID:
22349466
15.

Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?

Aagaard L, Soendergaard B, Stenver DI, Hansen EH.

Br J Clin Pharmacol. 2008 Mar;65(3):364-76. Epub 2007 Oct 24.

16.

Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, de Graeff PA, Mol PG.

Drug Saf. 2011 Nov 1;34(11):1101-14. doi: 10.2165/11592060-000000000-00000.

PMID:
21981437
17.
18.

[Knowledge creation about adverse drug reactions in the paediatric population].

Aagaard L.

Ugeskr Laeger. 2013 Feb 4;175(6):342-5. Danish.

PMID:
23402239
19.

Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?

Yamada T, Kusama M, Hirai Y, Arnold F, Sugiyama Y, Ono S.

Ann Pharmacother. 2010 Dec;44(12):1976-85. doi: 10.1345/aph.1P153. Epub 2010 Nov 23.

PMID:
21098757
20.

Structures and processes in spontaneous ADR reporting systems: a comparative study of Australia and Denmark.

Aagaard L, Stenver DI, Hansen EH.

Pharm World Sci. 2008 Oct;30(5):563-70. doi: 10.1007/s11096-008-9210-y. Epub 2008 Mar 19.

PMID:
18350372
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk